Michael D. Blaszyk - 14 Jun 2022 Form 4 Insider Report for ImmunityBio, Inc. (IBRX)

Reporting relationship: Director
Issuer ticker: IBRX
Reported as of: 14 Jun 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 Jun 2022, 21:16:59 UTC
Prior SEC filing: 10 Jun 2022
Next SEC filing: 05 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Jason Liljestrom, as Attorney-in-Fact

Key filing fact

Michael D. Blaszyk filed Form 4 for ImmunityBio, Inc. (IBRX) on 15 Jun 2022.

Key facts

This page summarizes Michael D. Blaszyk's Form 4 filing for ImmunityBio, Inc. (IBRX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 15 Jun 2022, 21:16.

Change

Previous filing in this sequence was filed on 10 Jun 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IBRX transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +167,937
Change %
Price: $0.000000
Shares after: 167,937
Date: 14 Jun 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 167,937
Exercise price: $2.98
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 14, 2023 or the date immediately preceding the 2023 annual meeting of stockholders.